// App-Quantinova.ai

EP974 : EFFICACY AND SAFETY OF SELINEXOR, BORTEZOMIB, AND DEXAMETHASONE BASED ON REFRACTORY STATUS TO LENALIDOMIDE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: A POST-HOC ANALYSIS OF THE BOSTON STUDY

Researchers

Presenter

  • Xavier Leleu

Principal Investigators

  • Sundar Jagannath

  • Sosana Delimpasi

  • Maryana Simonova

  • Ivan Spicka

  • Ludek Pour

  • Iryrna Kriachok

  • Maria Gavriatopoulou

  • Meletios Dimopoulos

  • Halyna Pylypenko

  • Holger Auner

  • Reuben Benjamin

  • Christopher Venner

  • Mamta Garg

  • Andrew DeCastro

  • Yi Chai

  • Jatin Shah

  • Sebastian Grosicki

  • Paul Richardson

Medical Centers

  • National Cancer Institute MPH of Ukraine,Kiev,Ukraine

  • CHU Poitiers - Hopital La Miletrie, Poitiers, France

  • 'Cherkasy Regional Oncology Dispensary' of Cherkasy Regional Council, Regional Treatment and Diagnostic Hematology Center,Cherkasy,Ukraine

  • King's College Hosptial NHS Foundation Trust, London, United Kingdom

  • Hospital Universitario De Salamanca-IBSAL, Salamanca, Spain

  • Institute of Blood Pathology &amp

  • General Hospital Evangelismos, Athens, Greece

  • Dana-Farber Cancer Institute, Boston, MA, United States

  • School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

  • University Hospital Brno, Brno, Czech Republic

  • The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

  • University Hospitals Leicester NHS Trust, Leicester, United Kingdom

  • Cross Cancer Institute, Edmonton, AB, Canada

  • Karyopharm Therapeutics Newton MA United States

  • Prague General University Hospital, Prague, Czech Republic

  • National and Kapodistrian University of Athens, Athens, Greece

  • NCRI and Imperial College London, London, United Kingdom

  • Transfusion Medicine of National Academy of Medical Sciences of Ukraine,Lviv,Ukraine

  • Zespól Szpitałi Miejskich w Chorzowie, Chorzów,Chorzów,Poland

Locations

  • Ukraine

  • France

  • United Kingdom

  • Spain

  • Greece

  • United States

  • Czech Republic

  • Canada

  • Poland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Lenalidomide

  • Bortezomib

  • Selinexor

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Controlled

Phase

  • III

Study Id's

  • NCT03110562

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved